Moreover, from a biological standpoint, the application of a highly effective degrader of ER provides important insight into the persistent dependency on this pathway by HR+ breast cancers that have become refractory to multiple currently available endocrine therapies. This evidence concerns the gene ESR1 and breast cancer.